Availability and Affordability of Kidney Health Laboratory Tests around the Globe.
Availability and Affordability of Kidney Health Laboratory Tests around the Globe.
复制标题
DOI：
10.1159/000511848
复制
发表时间：
2020
影响因子：
4.2
通讯作者：
Bello AK
中科院分区：
文献类型：
--
作者：
Tummalapalli SL;Shlipak MG;Damster S;Jha V;Malik C;Levin A;Johnson DW;Bello AK
肾脏疾病是一个主要的全球公共卫生问题，肾脏健康措施的实验室测试对于诊断和监测至关重要。各国肾脏健康实验室检测的可获得性和可负担性尚未得到系统描述。国际肾脏病学会(ISN)与肾脏疾病：改善全球结果(KDIGO)争议会议的领导人合作，从2020年4月至6月对ISN-全球健康肾脏地图集(ISN-GKHA)受访者中具有代表性的子集进行了调查。我们评估了国家人均国民总收入与实验室检测可获得性和可负担性之间的关系。在受邀的33位区域肾病专家中，有24位(73%)作出了回应，代表了全球所有10个国家肾脏病研究所区域。肾脏健康实验室检查的可得性为：血肌酐(100%)、血清胱抑素C(67%)、尿白蛋白(96%)、尿肌酐(100%)和尿试纸条分析(100%)。以国际美元计算的IQR报销中位数为：血肌酐INT$6.61(3.42-8.84)，血清胱抑素C INT$31.51(17.36-46.25)，尿白蛋白INT$10.22(5.90-15.42)，尿肌酐INT$7.50(1.66-8.84)，尿微量白蛋白INT$6.26(2.56-8.40)。按世界银行收入组或按人均国民总收入计算的偿还额没有显著差异。肾脏健康实验室测试广泛可用，报销价值也有很大差异。要在各国在减缓肾脏疾病增长方面取得有意义的进展，获得负担得起的诊断技术至关重要。随着各国越来越多地考虑肾脏疾病检测和管理的国家战略，我们的结果与政策制定者和研究人员高度相关。
Kidney disease is a major global public health problem, and laboratory testing of kidney health measures is essential for diagnosis and monitoring. The availability and affordability of kidney health laboratory tests across countries has not been systematically described. The International Society of Nephrology (ISN), in partnership with leaders of a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, surveyed a representative subset of ISN-Global Health Kidney Atlas (ISN-GKHA) respondents from April – June, 2020. We assessed the association between country gross national income (GNI) per capita and laboratory testing availability and affordability. Of 33 regional expert nephrologists invited, 24 (73%) responded, representing all 10 ISN regions around the world. Availability of kidney health laboratory tests was: serum creatinine (100%), serum cystatin C (67%), urine albumin (96%), urine creatinine (100%), and dipstick urinalysis (100%). Median (IQR) reimbursement values in international dollars were: serum creatinine Int$ 6.61 (3.42 – 8.84), serum cystatin C Int$ 31.51 (17.36 – 46.25), urine albumin Int$ 10.22 (5.90 – 15.42), urine creatinine Int$ 7.50 (1.66 – 8.84), and dipstick urinalysis Int$ 6.26 (2.56 – 8.40). Reimbursement values did not differ significantly by World Bank income group or by GNI per capita. There was widespread availability of kidney health laboratory tests and substantial variation in reimbursement values. To achieve meaningful progress across nations in mitigating the growth of kidney disease, access to affordable diagnostic technology is essential. Our results are highly relevant to policymakers and researchers as countries increasingly consider national strategies for kidney disease detection and management.
登录
查看更多内容
影响因子：
3.7
作者：
Sutton AJ;Breheny K;Deeks J;Khunti K;Sharpe C;Ottridge RS;Stevens PE;Cockwell P;Kalra PA;Lamb EJ;eGFR-C study group
通讯作者：
eGFR-C study group
影响因子：
7.7
作者：
Caramori, ML;Fioretto, P;Mauer, M
通讯作者：
Mauer, M
影响因子：
2.8
作者：
Ismail, Ola Z.;Bhayana, Vipin;Filler, Guido
通讯作者：
Filler, Guido
影响因子：
168.9
作者：
Bikbov, Boris;Purcell, Carrie;Vos, Theo
通讯作者：
Vos, Theo
影响因子：
13.2
作者：
White, Sarah L.;Yu, Richard;Chadban, Steven J.
通讯作者：
Chadban, Steven J.